Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis.
Twelve patients receiving lung transplants between 1988 and 1992 who developed clinical and histological features of obliterative bronchiolitis (OB) were compared with a group of 13 patients with good stable lung function (FEV1 more than 80% of predicted). Histological features of 180 biopsies were studied from the first postoperative year in order to assess whether any were associated with the development of OB. Clinically and histologically defined pulmonary rejection occurring after the first month was more frequent in OB patients (P = 0.03). Organizing pneumonia that was associated with acute rejection but not with nonviral infection was also seen more frequently in OB patients (P = 0.003). When all available lung transplant recipients surviving beyond 18 months were included in analyses, organizing pneumonia in the first year was associated with an increased relative risk of developing OB of 2.26 (95% CL 1.19-4.29), and the occurrence of coexistent organizing pneumonia and pulmonary rejection gave a relative risk for OB of 6.33 (95% CL 1.61-24.94). An increased incidence of histologically defined organizing pneumonia in OB patients has not been described previously. Furthermore the coexistence of organizing pneumonia with pulmonary rejection in the first year posttransplantation is a strong predictive factor for the development of OB.
Milne
D S
DS
University Department of Pathology, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom.
Gascoigne
A D
AD
Ashcroft
T
T
Sviland
L
L
Malcolm
A J
AJ
Corris
P A
PA
D000328:Adult; D001707:Biopsy, Needle; D001989:Bronchiolitis Obliterans / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D002648:Child; D005260:Female; D005541:Forced Expiratory Volume; D006084:Graft Rejection / Q000473:pathology / Q000503:physiopathology*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016040:Lung Transplantation / Q000009:adverse effects* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D012129:Respiratory Function Tests; D015996:Survival Rate; D013997:Time Factors